The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 16, 2013
Filed:
Jun. 11, 2008
Enrico Cappelletti, Sergno, IT;
Luciano Lattuada, Bussero, IT;
Karen E. Linder, Kingston, NJ (US);
Edmund R. Marinelli, Lawrenceville, NJ (US);
Palaniappa Nanjappan, Princeton, NJ (US);
Adrian D. Nunn, Lambertville, NJ (US);
Natarajan Raju, Kendall Park, NJ (US);
Kondareddiar Ramalingam, Dayton, NJ (US);
Rolf E. Swenson, Princeton, NJ (US);
Michael F. Tweedle, Princeton, NJ (US);
Mary Ellen Maddalena, Monmouth Jct., NJ (US);
Enrico Cappelletti, Sergno, IT;
Luciano Lattuada, Bussero, IT;
Karen E. Linder, Kingston, NJ (US);
Edmund R. Marinelli, Lawrenceville, NJ (US);
Palaniappa Nanjappan, Princeton, NJ (US);
Adrian D. Nunn, Lambertville, NJ (US);
Natarajan Raju, Kendall Park, NJ (US);
Kondareddiar Ramalingam, Dayton, NJ (US);
Rolf E. Swenson, Princeton, NJ (US);
Michael F. Tweedle, Princeton, NJ (US);
Mary Ellen Maddalena, Monmouth Jct., NJ (US);
Bracco Imaging S.p.A., Milan, IT;
Abstract
Novel methods of treating prostate tumors or of delaying the progression of prostate tumors are also provided, including, methods of treating bone or soft tissue metastases of prostate cancer methods for treating hormone sensitive and hormone refractory prostate cancer, methods for delaying the progression of hormone sensitive prostate cancer, for facilitating combination therapy in patients with hormone sensitive prostate cancer and for decreasing aberrant vascular permeability in patients with hormone sensitive prostate cancer, said methods comprising the step of administering to a subject a dose comprising an amount of radioactively labeled L70, N-[4-[[[[[4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]acetyl]amino]benzoyl]-L-glutaminyl-L-tryptophyl-L-alanyl-L-valyl-glycyl-L-histidyl-L-leucyl-L-methioninamide.